Bioterrorism and the Food Supply: Congress Poised to Give FDA Broad New Enforcement Authorities Over Foods
by John W. Bode, Principal in the law firm of Olsson, Frank and Weeda, P.C., Washington, D.C.
and
Karen R. Harned, formerly an Associate in the law firm of Olsson, Frank and Weeda, P.C., is Executive Director of the National Federation of Independent Business Legal Foundation, Washington, D.C.

Bioterrorism Preparedness in the Americas
by David Brandling-Bennett, M.D., Deputy Director of the Pan American Health Organization, Washington, D.C.

Efforts to Improve the Availability and Effective Use of Information to Optimize Health Outcomes in Terrorism and Other Urgent Events
by Melvyn Greberman, M.D., M.P.H., FACPM, Clinical Research Consultant, Department of Radiology, at the Walter Reed Army Medical Center, Washington, D.C.

Evaluating and Responding to the Threat of Bioterrorism in Industrial Facilities
by Frederick H. Branding, R.Ph., J.D., Bell, Boyd and Lloyd, with offices in Chicago, IL and Washington, D.C. and Michael K. Ohm, Bell, Boyd and Lloyd, with offices in Chicago, IL and Washington, D.C.

Will the State Emergency Preparedness Match Federal Response and Recovery?
by Christine M. Grant, J.D., M.B.A., Vice President of Public Policy and Government Relations at Aventis Pasteur USA, Swiftwater, PA.

Why Privatizing Management of Research and Development Is the Most Effective Way to Address the Threat of Bioterrorism
by Robert G. Pinco, Head of the Biomedical/FDA Group and co-chair of the worldwide biotechnology practice, in the law firm of Buchanan Ingersoll, P.C., Washington, D.C. and Todd Halpern, Associate in the Biomedical/FDA Group of the law firm of Buchanan Ingersoll, P.C., Washington, D.C.

Avoiding Liability for Injuries Suffered by Recipients of Vaccines and Drugs Administered in Response to Bioterrorism
by Michael T. Scott, Partner in the law firm of Reed Smith LLP, Philadelphia, PA

The Anthrax Vaccine Controversy
by John J. Michels, Jr., Partner in the law firm of McGuireWoods LLP, McLean, VA.

FDLI's Bioterrorism Conference Crystallizes Public Policy Issues
by Jacqueline Eng, President of Jacqueline Eng Consulting, LLC, Cooksville, MD.

What You Say May Be Used Against You
by John R. Fleder, Partner in the law firm of Hyman, Phelps & McNamara, P.C., Washington,D.C. and David B. Clissold, Associate in the law firm of Hyman, Phelps & McNamara, P.C., Washington, D.C.

China Revisits Food Safety
by Cynthia Blumenthal, Specialist in Regulatory Affairs with Genencor International Inc., Palo Alto, CA.

The Dietary Supplement Health and Education Act: Use it or Lose it
by Thomas N. Tiedt, Ph.D., Director of Med-Tox Group and drug and dietary supplement consultant, Longboat Key, FL.

Enforcement Corner
Personal Responsibility and Personal Jeopardy: FDA's Prosecution of Individuals
by Steven M. Kowal, Partner in the law firm of Bell, Boyd & Lloyd, Chicago, IL.

Global Corner
A Global Approach to Fighting Bioterrorism
by Matthew Weinberg, Chief Executive Officer of THE WEINBERG GROUP, INC., Washington, D.C.

Associates' Corner
Not Writing on a Clean Slate: Implementation of New Bioterrorism Legislation Will Require Attention to Existing Law
by Coleen Klasmeier, Associate with the law firm of Covington & Burling, Washington, D.C.

Note: All author affiliations are current as of the date of publication of the issue.